{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-016762","form_type":"8-K","ticker":"BLGO","cik":"0000880242","company_name":"BIOLARGO, INC.","filed_at":"2024-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.267462+00:00","generated_at":"2026-06-01T23:57:21.215100+00:00","sec_items":["7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"BioLargo reports record Q1 revenue, positive operating cash flow of $481K","bullets":["Q1 2024 revenue $4.76M, up 28% YoY and 9% QoQ; generated $481K positive operating cash flow.","Net loss $775K including $623K non-cash equity comp; stockholder's equity rose from $4.2M to $5.1M.","Launched water equipment subsidiary for PFAS treatment; appointed Sally Gutierrez, Jeffrey Kightlinger, Larry Dick to board.","EPA finalized PFAS regulations expected to favor BioLargo's treatment technology due to high efficacy and low waste."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-016762","json":"https://secwatch.observer/filing/0001437749-24-016762.json","markdown":"https://secwatch.observer/filing/0001437749-24-016762.md","text":"https://secwatch.observer/filing/0001437749-24-016762.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/880242/000143774924016762/0001437749-24-016762-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/880242/000143774924016762/blgo20240514_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T23:57:21.215100+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}